Cardiff Oncology shares plunge after Q2 earnings miss
Marsh & McLennan Companies, Inc. (NYSE:MMC) reached an all-time high this trading session, with its stock price soaring to $235.63. The global professional services firm, known for its expertise in risk, strategy, and people, has shown a remarkable performance over the past year, with a 1-year change showing an impressive 14.1% increase. This milestone reflects investor confidence in Marsh & McLennan’s robust business model and its ability to navigate the complexities of the current economic landscape. The company’s ascent to this record price level underscores its continued growth trajectory and solidifies its position as a leader in the industry.
In other recent news, Marsh & McLennan reported strong financial results for the fourth quarter of 2024, surpassing analyst expectations. The company achieved an adjusted earnings per share (EPS) of $1.87, beating the forecasted $1.77, and generated revenue of $6.07 billion, exceeding the projected $5.93 billion. Marsh & McLennan is also expanding its investment advisory capabilities through its announced acquisition of SECOR Asset Management, which is expected to close in the second quarter of 2025. This move aligns with Mercer (NASDAQ:MERC)’s strategy to enhance its wealth management services. Additionally, Raymond (NSE:RYMD) James increased Marsh & McLennan’s price target to $250, maintaining a Strong Buy rating, while Keefe, Bruyette & Woods adjusted their target to $210 with an Underperform rating. Goldman Sachs reiterated a Sell rating, setting the price target at $204, citing challenges in achieving growth and margin estimates. These developments provide investors with the latest insights into Marsh & McLennan’s financial performance and strategic initiatives.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.